PROGRAM |
|
|
|
13:30 |
Welcome & Business Meeting |
Lawrence L. Wald, Ph.D. |
|
|
A.A. Martinos Center MGH, USA |
|
|
|
13:35 |
Invited Presentations: What is Needed to Bring 7T to the
Clinic? |
|
|
|
|
13:40 |
Overview: What is Needed to Bring 7T to the Clinic? |
Stefan Schönberg, M.D. |
|
|
University Medical Centre Mannheim, Germany |
|
|
|
14:00 |
What's Needed for MSK? |
Siegfried Trattnig, M.D. |
|
|
Medical University of Vienna, Austria |
|
|
|
14:15 |
What's Needed for Body/Cancer? |
Tom W. J. Scheenen, Ph.D. |
|
|
Radboud Univ. Nijmegen Medical Center, The Netherlands |
|
|
|
14:30 |
What's Needed for Neuro? |
Michael V. Knopp, M.D., Ph.D. |
|
|
The Ohio State University, USA |
|
|
|
14:45 |
Rapid Abstract Presentations: Clinical
Use of >7T |
|
|
|
|
|
1H
MRS Study of Metabolic Alternations in Schizophrenia |
Zhongxu An, B.Sc. |
|
at 7T |
UT Southwestern Medical Center, USA |
|
|
|
|
The Three-Dimensional Shape of the Myopic Eye Measured |
Jan-Willem M. Beenakker, Ph.D. |
|
with MRI |
Leiden University Medical Center, The Netherlands |
|
|
|
|
7T Imaging of Patients with Focal Epilepsy Who Appear |
Rebecca E. Feldman, Ph.D. |
|
Non-Lesional in Diagnostic 1.5T & 3T MRI Scans: First
Results |
Icahn School of Medicine at Mount Sinai, USA |
|
|
|
|
Ultra-short TE
STEAM Improves Hepatic Lipid Quantification |
Martin Gajdosik, M.Sc. |
|
& Profiling at 7T |
Medical University of Vienna, Austria |
|
|
|
|
Comparing Different Contrasts for Myelin-related Cortical |
Roy Haast, M.Sc. |
|
Mapping at 7T |
Maastricht University, The Netherlands |
|
|
|
|
A Parkinson's Disease 31P-MRSI
Study at 7T |
Silvina G. Horovitz, Ph.D. |
|
|
National Institute of Neurological Disorder, USA |
|
|
|
|
High Percentage of MS Lesions Found to Have a Central Vein |
Zahra Hosseini, M.Appl.Sc. |
|
Using Single Slice SWI at 7 Tesla |
Robarts Research Institute, Canada |
|
|
|
|
Enhanced Functional Connectivity between Sub-regions in the |
Jun Hua, Ph.D. |
|
Thalamus & Cortex in Schizophrenia Patients Measured by |
Johns Hopkins University School of Medicine, USA |
|
Resting State BOLD fMRI at 7T |
|
|
|
|
|
A Comprehensive 7 Tesla MRI Protocol for Quantitative (T1-,
T2-, |
Andrea Lazik, M.D. |
|
T2*-Mapping)
& Morphological Hip Cartilage Imaging |
University Hospital Essen, Germany |
|
|
|
|
Evaluating Brain Metabolites in Patients with Glioma Using
Short |
Yan Li, M.D., Ph.D. |
|
& Long TE MRSI at 3T & 7T |
University of California, San Francisco, USA |
|
|
|
|
MR Imaging of the Temporomandibular Joint at 7.0 Tesla: A |
Ioan-Andrei Manoliu, M.D., Ph.D. |
|
Feasibility Study Using Novel High Permittivity Dielectric
Pads |
University Hospital Zurich, Switzerland |
|
|
|
|
In Vivo MR
Microscopy of the Nervus Opticus at 3.0 T & 7.0 T: |
Katharina M. Paul, Dipl.-Phys. |
|
Anatomical & Diffusion Weighted Imaging in Healthy Subjects |
Berlin Ultrahigh Field Facility (B.U.F.F.), Germany |
|
& Patients with Optic Nerve Glioma |
|
|
|
|
|
In Vivo
Quantification of Human Hippocampal Subfields in Health |
Clive Rosenthal, Ph.D. |
|
& in Organic Amnesia Using 7.0-Tesla 0.4mm2 3-D Fast Spin |
University of Oxford, United Kingdom |
|
Echo Imaging |
|
|
|
|
|
Comparison of QSM, T2-Relaxometry
& T2-Weighted
Imaging |
Petra Schmalbrock, Ph.D. |
|
at 7T for Assessment of Basal Ganglia Iron in MS Patients |
The Ohio State University, USA |
|
|
|
|
Phase Contrast MRI Differentiates between Brain Lesions in |
Tim Sinnecker, M.D. |
|
Neuromyelitis Optica & Multiple Sclerosis – Preliminary
Data |
Charité University Hospital, Germany |
|
from a 7T MRI Study |
|
|
|
|
|
Elevated Glutamate Concentrations in the Visual Cortex of |
Jannie P. Wijnen, Ph.D. |
|
Migraine without Aura Detected at 7 Tesla |
University Medical Centre Utrecht, The Netherlands |
|
|
|
|
T1rho
& T2
Relaxation Times in Patients with Knee Osteoarthritis |
Cory Wyatt, Ph.D. |
|
at 3 Tesla & 7 Tesla |
University of California, San Francisco, USA |
|
|
|
|
Relaxation-weighted Sodium MRI of Breast Lesions at 7T |
Stefan Zbyn, M.Sc. |
|
|
Medical University of Vienna, Austria |
|
|
|
15:15 |
Poster Awards & Concluding Remarks |
Lawrence L. Wald, Ph.D. |
|
|
A.A. Martinos Center MGH, USA |
15:30 |
Adjournment |
|